The Evolution of Targeted Therapies in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer
Cancers · 01.04.2026 · 18 (7) · 1130
DOI: 10.3390/cancers18071130 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 01.04.2026. Verfasst von Hyejee Ohm und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University of British Columbia, Vancouver, BC V5Z 4E6, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer is the second most common malignancy worldwide, and over 70% of new diagnosis are of the hormone receptor-positive (HR+) and HER2-negative (HER2−) subtype. The cornerstone in management of early stage HR+ breast cancer has historically consisted of chemotherapy and endocrine therapies. Genomic assays in early stage HR+HER2− breast cancer has provided a prognostic tool for recurrence and a predictive tool to select patients for adjuvant chemotherapy. The introduction of bone-modifying agents and adjuvant CDK 4/6 inhibitors into early stage disease represents new therapeutic modalities aimed at reducing risk in high-risk HR+HER2− cancers. This manuscript aims to provide a comprehensive overview of the evidence behind endocrine therapy and recommended duration of treatment, genomic assays to guide chemotherapy delivery, data guiding use of bisphosphonate therapy to reduce bone recurrence, and indications for incorporating CDK 4/6 inhibitors. In addition, novel endocrine agents and targeted therapies under investigation are highlighted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.
- Medical Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.
ORCID-Profile: Hyejee Ohm, Nathalie LeVasseur, Christine Simmons, Zahi I Mitri
Zitieren
APA
Ohm, H., Lohrisch, C., LeVasseur, N., Simmons, C., & Mitri, Z. I. (2026). The Evolution of Targeted Therapies in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer. Cancers, 18(7), 1130. https://doi.org/10.3390/cancers18071130
Vancouver
Ohm H, Lohrisch C, LeVasseur N, Simmons C, Mitri ZI. The Evolution of Targeted Therapies in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer. Cancers. 2026;18(7):1130. doi:10.3390/cancers18071130
BibTeX
@article{Ohm2026,
author = {Ohm, Hyejee and Lohrisch, Caroline and LeVasseur, Nathalie and Simmons, Christine and Mitri, Zahi I},
title = {The Evolution of Targeted Therapies in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {7},
pages = {1130},
doi = {10.3390/cancers18071130}
}
EUVIMED